Key facts
- This page summarizes Scott M. Plesha's Form 4/A - Amendment filing for Pelthos Therapeutics Inc. (PTHS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 01 Apr 2026, 17:44.
Scott M. Plesha - 02 Jul 2025 Form 4/A - Amendment Insider Report for Pelthos Therapeutics Inc. (PTHS)
- Reporting relationship
- CEO and President, Director
- Issuer ticker
- PTHS
- Reported as of
- 02 Jul 2025
- Net transaction value
- $0
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 01 Apr 2026, 17:44:11 UTC
- Original report date
- 23 Jul 2025
- Prior SEC filing
- 22 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Francis Knuettel II, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Scott M. Plesha filed Form 4/A - Amendment for Pelthos Therapeutics Inc. (PTHS) on 01 Apr 2026.
Change
- Previous filing in this sequence was filed on 22 Mar 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reporting Owners (1)
CIK 0001726687
Primary reporting owner
Plesha Scott M.
- Relationship
- CEO and President, Director
- Address
- C/O PELTHOS THERAPEUTICS INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM
- Signature
- /s/ Francis Knuettel II, by power of attorney
- Signature date
- 01 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PTHS
transaction
Common Stock
Award
- Transaction value
- Shares
- +83,678
- Change %
- Price
- $0.000000*
- Shares after
- 83,678
- Date
- 02 Jul 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I.
Footnote F2
The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.
SEC remarks
Exhibit 24 - Power of Attorney